ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
4
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,305
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
GlaxoSmithKline receives conditional marketing authorization in the EU for Arzerra (ofatumumab)
Author(s):
Publication date:
2010
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Karger: Oncology
Data availability:
ScienceOpen disciplines:
Oncology & Radiotherapy
,
Medicine
Comments
Comment on this article
Sign in to comment
Similar content
2,305
Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): Results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. [abstract]
Authors:
WG Wierda
,
TJ Kipps
,
J. Durig
Vertex enters agreement with GlaxoSmithKline for Phase 2 all-oral study of VX-135 and GSK2336805 for the treatment of hepatitis C [press release]
Authors:
GlaxoSmithKline to Pay $3bn in US Drug Fraud Scandal
Authors:
See all similar
Cited by
1
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
Authors:
Luca Laurenti
,
Idanna Innocenti
,
Francesco Autore
…
See all cited by